ANL — Adlai Nortye Group Ltd.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1944552 · Singapore
Last close
$9.48
Market Cap
$556.80M
52W High
$17.25
52W Low
$0.88
ADV30
322,060
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 — — — — 248,362,000 132,590,000 33,534,000
Dec 2025 — — — — 34,433,000 8,056,000 42,755,000
Jun 2025 — — — — 72,045,000 44,138,000 64,124,000

Balance + Analyst (yfinance extras)

Retained Earnings
$-470,182,000
Inventory
—
Receivables
$7,982,000
ST Investments
$100,227,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$18,056,000
EBITDA
$-21,650,500
Free Cash Flow
$-11,449,125
Enterprise Value
$773,376,640
Total Cash
$232,816,992
Total Debt
$26,701,000
Shares Out
58,734,604
Trailing EPS
$-0.66
Book Value
$3.34
ROE
-20.2%
ROA
-8.7%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 5,000,000 -35,698,000 -35,528,000 34,433,000 42,755,000 -8,322,000 -33,452,000
Dec 2024 0 -52,928,000 -51,869,000 71,270,000 45,785,000 25,485,000 -51,819,000
Dec 2023 0 -72,551,000 -109,228,000 130,189,000 55,143,000 75,046,000 -56,652,000
Dec 2022 0 -67,270,000 -58,790,000 72,594,000 313,887,000 -241,293,000 -43,223,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.29

Peers — same industry

TickerNameMarket CapLastDaily %
ZVRA ZEVRA THERAPEUTICS, INC. $559.34M $9.40 —
WVE Wave Life Sciences, Inc. $560.13M $2.84 —
AVBP ArriVent BioPharma, Inc. $552.92M $10.69 —
CLYM Climb Bio, Inc. $574.46M $9.78 —
ACRS Aclaris Therapeutics, Inc. $536.11M $3.38 —

News headlines (Yahoo Finance, 1h cache)

Adlai Nortye Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium
2026-10-27 20:05 · Yahoo
4.8x P B? Adlai Nortye Group (ANL) On Its AN4035 Trial Progress
2026-09-15 17:12 · Yahoo
Adlai Nortye Enters into Clinical Collaboration with Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab
2026-10-15 11:00 · Yahoo
Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?
2026-10-14 12:40 · Yahoo
Adlai Nortye Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations
2026-09-30 11:00 · Yahoo
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
2026-09-08 11:00 · Yahoo
These 2 ‘Monster Growth’ Stocks Aren’t Done Climbing, Say Analysts
2026-09-06 18:00 · Yahoo
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
2026-08-14 11:00 · Yahoo
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
2026-08-03 11:00 · Yahoo
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
2026-07-16 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.